Replimune Group (NASDAQ:REPL) Trading 5.3% Higher – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL) shares shot up 5.3% during mid-day trading on Friday . The company traded as high as $10.09 and last traded at $10.0230. 1,265,025 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 4,505,842 shares. The stock had previously closed at $9.52.

Analyst Ratings Changes

REPL has been the topic of a number of research reports. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price for the company in a report on Friday, June 26th. Wedbush boosted their price target on Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 30th. Finally, BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Replimune Group currently has a consensus rating of “Hold” and an average price target of $8.12.

Replimune Group Trading Up 7.1%

The firm’s 50 day moving average price is $8.56 and its 200-day moving average price is $7.37. The stock has a market cap of $855.85 million, a P/E ratio of -3.00 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts forecast that Replimune Group, Inc. will post -2.54 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently bought and sold shares of the business. International Assets Investment Management LLC bought a new stake in Replimune Group in the 4th quarter worth about $29,000. CWM LLC boosted its holdings in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC grew its stake in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Replimune Group during the second quarter valued at approximately $69,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.